News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 30, 2020, 15:18 ET At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19

At today's White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider...


Jul 09, 2020, 08:33 ET CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress

Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Award for coagulation research just ahead...


Jul 06, 2020, 08:33 ET In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress

Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and...


Jul 03, 2020, 02:30 ET IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product...


Jun 24, 2020, 18:28 ET CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an...


Jun 19, 2020, 14:03 ET Yi Deng and Bill Mezzanotte Elected to University City Science Center Board of Directors

The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June...


Jun 12, 2020, 08:20 ET CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH)...


Jun 08, 2020, 16:00 ET CSL Behring to Acquire Biotech Company Vitaeris

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused ...


Jun 08, 2020, 02:00 ET CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...


Jun 05, 2020, 08:30 ET The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered ...


Jun 02, 2020, 10:00 ET CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring...


May 07, 2020, 08:42 ET CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived...


Apr 21, 2020, 08:00 ET CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)

Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than currently...


Apr 08, 2020, 09:15 ET CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced today their...


Feb 13, 2020, 09:00 ET University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware

Researchers at the University of Pittsburgh and the University of Delaware have been awarded funding and support to accelerate their search for new...


Feb 11, 2020, 17:10 ET PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...


Jan 28, 2020, 07:03 ET CSL Behring: Respreeza aprobado como tratamiento estándar para la deficiencia de alfa-1 antitripsina

El líder global en bioterapéuticos CSL Behring ha anunciado hoy que la Agencia Danesa del Medicamento ha publicado su decisión final, aprobando la...


Jan 26, 2020, 10:58 ET Le Conseil danois des médicaments accorde une approbation en faveur de la protéine Respreeza de CSL Behring en tant que traitement standard pour les patients souffrant de graves déficits en alpha-1 antitrypsine

CSL Behring, leader mondial dans le domaine biothérapeutique, a annoncé aujourd'hui que le Conseil danois des médicaments a publié sa décision...


Jan 26, 2020, 10:51 ET Dänischer Arzneimittelrat erteilt Zulassung für CSL Behrings Respreeza als Standardbehandlung für Patienten mit schwerem Alpha-1-Antitrypsin-Mangel

CSL Behring, der globale Marktführer im Bereich der Biotherapeutika, gab heute bekannt, dass der Dänische Arzneimittelrat seine endgültige...


Jan 21, 2020, 11:21 ET Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity

Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six...


Jan 10, 2020, 08:57 ET Researchers decipher a new way that immune cells detect infections and cancers

Peer reviewed: Science Project funding: Australian Research Council, National Health and Medical Research Council, Cancer Council Victoria, the...


Jan 09, 2020, 12:35 ET Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference

Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will...


Dec 09, 2019, 08:19 ET HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...


Oct 24, 2019, 09:20 ET Harvard Business Review Names CSL's Paul Perreault Among Best Performing CEOs in the World

Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world...


Jul 01, 2019, 18:15 ET CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation ...